Piper Sandler lowered the firm’s price target on Aquestive Therapeutics (AQST) to $5 from $8 and keeps an Overweight rating on the shares.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AQST:
- Aquestive Therapeutics reports Q1 EPS (24c), consensus (16c)
- Aquestive Therapeutics Submits NDA for Anaphylm
- Aquestive Therapeutics, Inc. (AQST) Q1 Earnings Cheat Sheet
- Buy Rating Affirmed for Aquestive Therapeutics Amid Promising Anaphylm Developments and Strategic Progress
- Optimistic Buy Rating for Aquestive Therapeutics Driven by Anaphylm’s Promising NDA Submission and Clinical Success